# Combination of Cetuximab With Afatinib for Patient With EGFR Mutated Lung Cancer

> **NCT02716311** · PHASE2 · COMPLETED · sponsor: **Intergroupe Francophone de Cancerologie Thoracique** · enrollment: 118 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Afatinib
- **DRUG:** Cetuximab

## Key facts

- **NCT ID:** NCT02716311
- **Lead sponsor:** Intergroupe Francophone de Cancerologie Thoracique
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05
- **Primary completion:** 2019-02
- **Final completion:** 2021-04-07
- **Target enrollment:** 118 (ACTUAL)
- **Last updated:** 2022-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02716311

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02716311, "Combination of Cetuximab With Afatinib for Patient With EGFR Mutated Lung Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02716311. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*